Selling a Fertility Clinic in 2026: Multiples, Named Buyers, and the IVF Operator Playbook

If you own a fertility clinic in 2026, the M&A market is one of the most active healthcare subsegments. Inception Fertility (Lee Equity Partners + Morgan Stanley Capital) is the largest US fertility platform with ~$500M+ revenue post Prelude Fertility integration. Pinnacle Fertility (PE-backed) operates a multi-state platform. US Fertility (Lee Equity Partners + Amulet Capital) is a major PE-backed roll-up. Kindbody (Perceptive Advisors + RRE Ventures) is the tech-enabled clinic + employer-benefit platform. IVI/RMA / Eugin Group (KKR-backed) operates global. Progyny Inc. (NASDAQ: PGNY) is the dominant US fertility benefits manager, not a direct clinic acquirer but a critical network partner.

What the asset is worth depends on three things: (1) REI provider bench depth (board-certified reproductive endocrinology & infertility specialists are scarce and create transferability premium), (2) modern embryology lab with CLIA + CAP-RT accreditation and IVF success rates above the SART national average, and (3) named employer-benefit network status (Progyny, Carrot, Maven). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

Named fertility M&A transactions (2021-2025)

The named buyer landscape

National PE-backed fertility platforms

• Inception Fertility (Lee Equity Partners + Morgan Stanley Capital, ~$500M+ revenue) — the largest US fertility platform post Prelude Fertility integration in 2022.
• US Fertility (Lee Equity Partners + Amulet Capital) — multi-state PE-backed platform.
• Pinnacle Fertility (PE-backed) — multi-state platform.
• IVI/RMA / Eugin Group (KKR-backed) — global fertility platform with significant US presence (includes Boston IVF).
• Kindbody (Perceptive Advisors + RRE Ventures + Worth Venture Partners) — tech-enabled multi-state clinic + employer-benefit platform.
• Sebawe Fertility Care (PE-backed) — regional.

Employer fertility benefits managers (network partners, not direct clinic acquirers)

• Progyny Inc. (NASDAQ: PGNY, $1.2B+ revenue) — the dominant US fertility benefits manager.
• Carrot Fertility — employer fertility benefits.
• Maven Clinic — women’s and family health benefits manager with fertility coverage.

PE sponsors active in this space

• Lee Equity Partners (Inception Fertility + US Fertility), Morgan Stanley Capital (Inception co-sponsor), Amulet Capital (US Fertility co-sponsor), KKR (IVI/RMA / Eugin Group), Perceptive Advisors + RRE Ventures + Worth Venture Partners (Kindbody), plus multiple healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: REI (Reproductive Endocrinology & Infertility) board-certified provider bench (REI specialists are scarce, ~1,400 in the US), modern embryology lab with CLIA + CAP-RT (Reproductive Tissues) accreditation, IVF success rates above SART (Society for Assisted Reproductive Technology) national average (live birth per oocyte retrieval, by age band), named employer-benefit network status (Progyny, Carrot, Maven), state-mandated fertility coverage market footprint (NJ, NY, IL, MA, CA, others), modern EMR (eIVF, IDEAS by IVF Solutions, ARTworks, Fertility Cloud), multi-state licensure, integrated genetic testing (PGT, NIPT) and oncofertility services.
• Will compress or reject: single-MD REI dependence (transferability risk), lab not CAP-RT accredited, IVF success rates below SART national average, no employer-benefit network status, single-state without mandated-coverage growth path, legacy EMR or paper-based lab workflow, weak embryology team retention.

The operator-level KPI playbook buyers will diligence

Provider bench and laboratory

• REI provider count and tenure: Board-certified Reproductive Endocrinology & Infertility specialists. Only ~1,400 in the US.
• Embryologist count and certification: ART Embryology Lab Director (HCLD), Technical Supervisor.
• Andrologist coverage.
• RN and patient coordinator staffing ratios.

IVF success rates

• SART (Society for Assisted Reproductive Technology) reporting: Annual SART data submission and CDC ART reporting.
• Live birth per oocyte retrieval by age band: Compare to SART national average for each age band (<35, 35-37, 38-40, 41-42, >42).
• Pregnancy rate per embryo transfer.
• Miscarriage rate.
• Multiple pregnancy rate (twins+).
• Time-to-pregnancy metrics.

Payer mix and contracting

• Self-pay percentage: Out-of-pocket IVF cycles ($15k-$25k+ per cycle).
• Employer benefits-managed percentage: Progyny, Carrot, Maven enrollee patients.
• State-mandated coverage: Patients with state-mandated fertility insurance (NJ, NY, IL, MA, CA, CT, etc.).
• Commercial insurance percentage: Direct commercial-payer relationships.
• Single-payer or single-employer concentration.

Service-line mix

• IVF cycles per year: Total fresh and frozen embryo transfer (FET) cycles.
• IUI (intrauterine insemination) cycles.
• Egg freezing volume: Growing category.
• Embryo banking volume.
• PGT (preimplantation genetic testing) attach rate.
• Donor egg, donor sperm, gestational carrier volumes.
• Oncofertility services.

Laboratory operations

• CLIA + CAP-RT (Reproductive Tissues) accreditation status.
• Lab quality metrics: Embryo grade distribution, fertilization rates, blastocyst conversion rates.
• Equipment age and maintenance: Incubators, micromanipulators, time-lapse imaging.
• Cryostorage capacity and growth.
• Lab workflow software.

EMR and operating system

• EMR: eIVF (the fertility operator standard), IDEAS by IVF Solutions, ARTworks, Fertility Cloud, Babyscripts.
• Integration with embryology lab software.
• Patient portal and engagement.

Dangers and traps in fertility clinic M&A

1. Single-MD REI dependence

REI specialists are scarce (~1,400 in the US). Single-MD-REI dependence is a real transferability risk; build the provider bench.

2. Lab accreditation gaps

CLIA + CAP-RT accreditation is non-negotiable. Findings or lapses are deal-killers.

3. IVF success rates below SART national average

SART data is publicly reported. Success rates below the age-band national average compress the multiple materially.

4. No employer-benefit network status

Progyny, Carrot, and Maven enrollment is increasingly important for clinic volume and revenue mix. No network status compresses.

5. Single-state without mandated-coverage growth path

State-mandated fertility coverage is expanding. Single-state operators without mandated-coverage growth opportunity compress.

6. Embryo storage liability

Cryostorage incidents (loss of patient embryos, mislabeling, mix-ups) are catastrophic both for patient relationships and for malpractice. Document chain of custody, redundancy, and incident history.

7. Donor and gestational carrier compliance

FDA tissue donor screening, state-specific gestational carrier laws, ART industry guidelines — all must be documented.

8. Equity-rollover expectations

PE-fertility deals typically include 30-50% equity rollover plus multi-year earnouts to mitigate REI transferability risk.

Our POV on fertility clinic M&A in 2026

Fertility is one of the most active healthcare M&A subsegments driven by employer-benefit mandate expansion (Progyny, Carrot, Maven), state-mandated fertility coverage growth, and demographic trends. Inception Fertility (Lee Equity Partners + Morgan Stanley Capital) is the largest US fertility platform. US Fertility (Lee Equity + Amulet Capital), Pinnacle Fertility, Kindbody, and IVI/RMA (KKR) are the other major platforms. Premium multiples require REI provider bench depth, CAP-RT accredited modern lab, IVF success above SART average, and named employer-benefit network status.

Preparing your fertility clinic for sale: 12-18 months out

1. Get multi-year audited or reviewed financials. Document cycle volume, payer mix, success rates.
2. Build REI provider bench. Reduce single-MD dependence.
3. Maintain CAP-RT lab accreditation. No findings, no lapses.
4. Improve IVF success rates. Lab QC, embryologist training, protocol optimization.
5. Pursue employer-benefit network status. Progyny, Carrot, Maven.
6. Document state-mandated coverage market footprint.
7. Modernize EMR. eIVF, IDEAS, ARTworks, Fertility Cloud.
8. Document embryo cryostorage chain of custody.
9. Run a competitive process. Inception Fertility (Lee Equity Partners + Morgan Stanley Capital), US Fertility (Lee Equity + Amulet Capital), Pinnacle Fertility, Kindbody (Perceptive Advisors + RRE Ventures), IVI/RMA / Eugin Group (KKR), plus PE sponsors directly.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a fertility clinic in 2026?

Single-MD REI fertility practices ($500k-1.5M EBITDA) typically sell at 5x-7x EBITDA. Multi-MD single-site or 2-3 location practices ($1.5-4M EBITDA) go 6x-9x. Small regional fertility groups with 3-10 REI providers ($3-8M EBITDA) go 7x-10x. Mid-size fertility platforms ($5-15M EBITDA, multi-state, multi-MD REI, integrated lab) go 9x-12x. Premium scale platforms ($15M+ EBITDA, multi-state, CAP-RT accredited lab, IVF success above SART average, named employer-benefit contracts) reach 10x-14x+.

Who are the active buyers of fertility clinics right now?

National PE-backed fertility platforms: Inception Fertility (Lee Equity Partners + Morgan Stanley Capital, ~$500M+ revenue, largest US fertility platform post Prelude Fertility integration), US Fertility (Lee Equity Partners + Amulet Capital), Pinnacle Fertility, IVI/RMA / Eugin Group (KKR-backed, global with US presence including Boston IVF), Kindbody (Perceptive Advisors + RRE Ventures + Worth Venture Partners, tech-enabled). PE sponsors: Lee Equity Partners, Morgan Stanley Capital, Amulet Capital, KKR, Perceptive Advisors + RRE Ventures. Employer benefits managers (network partners, not direct acquirers): Progyny Inc. (NASDAQ: PGNY), Carrot Fertility, Maven Clinic.

What hurts a fertility clinic’s valuation most?

Single-MD REI dependence with weak provider bench (REI specialists are scarce, ~1,400 in the US), lab not CAP-RT (Reproductive Tissues) accredited, IVF success rates below SART national average, no employer-benefit network status (Progyny/Carrot/Maven), single-state without mandated-coverage growth path, legacy EMR or paper-based lab workflow, weak embryology team retention, and any cryostorage incident history.

Why are employer fertility benefits managers so important?

Employer-mandated fertility benefits have expanded dramatically since 2020. Progyny Inc. (NASDAQ: PGNY) is the dominant US fertility benefits manager with ~$1.2B+ revenue, contracting directly with large employers (Microsoft, Meta, JPMorgan, etc.) to provide fertility benefits to employees. Carrot Fertility and Maven Clinic are competitors. Clinics with named network status with these benefit managers capture employer-channel patient volume that is otherwise hard to access. Network status is a real multiple-builder.

What is SART and why does it matter?

SART (Society for Assisted Reproductive Technology) is the US ART industry body that collects and publicly reports IVF outcomes by clinic. SART publishes annual data on live birth per oocyte retrieval by age band, fertilization rates, multiple pregnancy rates, and other quality metrics. Buyer-side diligence pulls SART data directly. Clinics with success rates above SART national average for each age band achieve premium multiples; below-average clinics compress.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

How long does it take to sell a fertility clinic?

Once you go to market with a buyer-paid advisor, a typical process runs 6-10 months from initial outreach to closing, with regulatory and lab-accreditation diligence extending the timeline. Add 12-18 months of preparation work before going to market.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Highest-leverage pre-sale work: build REI provider bench (reduce single-MD dependence), maintain CAP-RT lab accreditation, improve IVF success rates above SART average, pursue Progyny/Carrot/Maven employer-benefit network status, and document embryo cryostorage chain of custody.

Related research

• How to sell an ophthalmology practice
• How to sell a dermatology practice
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell a clinical laboratory
• How to sell an imaging center
• How to sell a MedSpa
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch